These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20943770)

  • 1. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.
    Belibi F; Ravichandran K; Zafar I; He Z; Edelstein CL
    Am J Physiol Renal Physiol; 2011 Jan; 300(1):F236-44. PubMed ID: 20943770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y; Kim J; Schrier RW; Edelstein CL
    J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
    Tao Y; Kim J; Faubel S; Wu JC; Falk SA; Schrier RW; Edelstein CL
    Proc Natl Acad Sci U S A; 2005 May; 102(19):6954-9. PubMed ID: 15863619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
    Zafar I; Belibi FA; He Z; Edelstein CL
    Nephrol Dial Transplant; 2009 Aug; 24(8):2349-53. PubMed ID: 19321761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
    Liu C; Li H; Gao X; Yang M; Yuan L; Fu L; Wang X; Mei C
    Am J Physiol Renal Physiol; 2018 May; 314(5):F844-F854. PubMed ID: 26911848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease.
    Ecder T; Melnikov VY; Stanley M; Korular D; Lucia MS; Schrier RW; Edelstein CL
    Kidney Int; 2002 Apr; 61(4):1220-30. PubMed ID: 11918728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
    Banković-Calić N; Ogbori MR; Nicman E
    Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.
    Wahl PR; Le Hir M; Vogetseder A; Arcaro A; Starke A; Waeckerle-Men Y; Serra AL; Wuthrich RP
    Nephrology (Carlton); 2007 Aug; 12(4):357-63. PubMed ID: 17635750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation Is More Sensitive than Cell Proliferation in Response to Rapamycin Treatment in Polycystic Kidney Disease.
    Yang M; Lv J; Gong C; Xue C; Fu L; Chen S; Mei C
    Kidney Blood Press Res; 2024; 49(1):60-68. PubMed ID: 38167222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment with 2-deoxy-d-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (PKD).
    Atwood D; He Z; Miyazaki M; Hailu F; Klawitter J; Edelstein CL
    Cell Signal; 2024 Nov; 123():111351. PubMed ID: 39159908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling.
    Yano T; Ferlito M; Aponte A; Kuno A; Miura T; Murphy E; Steenbergen C
    Circ Res; 2014 Apr; 114(8):1268-80. PubMed ID: 24557881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
    Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.
    Turner CM; Ramesh B; Srai SK; Burnstock G; Unwin RJ
    Cells Tissues Organs; 2004; 178(3):168-79. PubMed ID: 15655334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease.
    Zhang T; Wang L; Xiong X; Mao Z; Wang L; Mei C
    Biol Res; 2009; 42(4):437-44. PubMed ID: 20140299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
    Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
    Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium.
    Harston RK; McKillop JC; Moschella PC; Van Laer A; Quinones LS; Baicu CF; Balasubramanian S; Zile MR; Kuppuswamy D
    Am J Physiol Heart Circ Physiol; 2011 May; 300(5):H1696-706. PubMed ID: 21357504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.